Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...

Bayer's two-year-old digital health collaboration ... one-on-one coaching and heart health advice – all delivered and organised via an app. The first iteration of the software is aimed at ...

Bayer Leverkusen boss Xabi Alonso was delighted with the reaction his side showed after they won a dramatic DFB-Pokal quarter ...

This collaboration supports the "Protect Your Heart" national awareness campaign, sponsored by Bayer and Al-Dawaa Medical ...

Bayer plans to launch Acoramidis, a treatment for a rare heart disease called transthyretin amyloid cardiomyopathy, near the end of the first quarter, as well as elinzanetant, a non-hormonal ...

Bayer seeks European marketing approval for use of finerenone in adult patients with HF with a left ventricular ejection fraction (LVEF) of =40%: Berlin Tuesday, February 4, 2025, ...

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients ...